Myalepta (Metreleptin)

Metreleptin, the active ingredient in Myalepta, is a leptin analog (recombinant human leptin) presented as a sterile injectable solution for subcutaneous use. It is indicated for patients with generalized lipodystrophy and congenital leptin deficiency to restore leptin signaling and improve metabolic control.

GNH USA supplies Myalepta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products, ensuring product integrity from manufacture to delivery.

Myalepta acts on the leptin pathway to address metabolic abnormalities associated with lipodystrophy and leptin deficiency. - Generalized lipodystrophy: improves insulin sensitivity and reduces hypertriglyceridemia. - Leptin deficiency: restores normal appetite regulation and energy expenditure. - Metabolic complications of lipodystrophy: helps lower hepatic steatosis and improves glycemic control.

Metreleptin may be associated with several adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site erythema or pain - Headache - Nausea - Abdominal discomfort - Fatigue - Mild hypoglycemia

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions - Development of anti‑leptin antibodies leading to loss of efficacy - Autoimmune disease exacerbation - Severe infections - Pancreatitis - Potential malignancy signals (rare)

When prescribing Myalepta, clinicians should observe several precautionary measures to ensure patient safety. - Monitor metabolic parameters: regularly assess triglycerides, glucose, and liver enzymes. - Screen for anti‑leptin antibodies: evaluate efficacy and risk of immune reactions. - Use with caution in hepatic impairment: adjust monitoring due to altered metabolism. - Avoid in patients with known hypersensitivity to metreleptin or formulation components. - Pregnancy and lactation: safety not established; weigh potential benefits against unknown risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metreleptin can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: reduced vaccine efficacy, avoid concurrent administration. - Concurrent leptin analogs or investigational leptin therapies: additive effects unknown, avoid co‑administration.

Moderate Interactions (Monitor Closely): - Insulin or insulin secretagogues: increased risk of hypoglycemia, monitor blood glucose. - Immunosuppressive agents: heightened infection risk, observe clinical status. - Hormonal contraceptives: possible alteration of leptin levels, assess contraceptive effectiveness.